MILESTONE PHARMACEUTICALS IN's ticker is MIST and the CUSIP is 59935V107. A total of 48 filers reported holding MILESTONE PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 61.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,786,048 | -26.3% | 1,353,067 | 0.0% | 0.00% | – |
| Q1 2024 | $2,421,990 | +7.2% | 1,353,067 | 0.0% | 0.00% | – |
| Q4 2023 | $2,259,622 | -71.5% | 1,353,067 | -47.1% | 0.00% | -100.0% |
| Q3 2023 | $7,932,044 | +8.9% | 2,558,724 | +0.1% | 0.00% | 0.0% |
| Q2 2023 | $7,282,568 | -27.6% | 2,555,287 | +0.1% | 0.00% | 0.0% |
| Q1 2023 | $10,056,712 | -4.1% | 2,552,465 | -3.6% | 0.00% | -33.3% |
| Q4 2022 | $10,482,579 | +1091835.3% | 2,647,116 | +2433.2% | 0.00% | – |
| Q3 2022 | $960 | +1197.3% | 104,497 | +770.5% | 0.00% | – |
| Q2 2022 | $74 | -99.9% | 12,004 | 0.0% | 0.00% | – |
| Q1 2022 | $77,000 | -2.5% | 12,004 | 0.0% | 0.00% | – |
| Q4 2021 | $79,000 | +14.5% | 12,004 | 0.0% | 0.00% | – |
| Q3 2021 | $69,000 | +4.5% | 12,004 | 0.0% | 0.00% | – |
| Q2 2021 | $66,000 | -5.7% | 12,004 | 0.0% | 0.00% | – |
| Q1 2021 | $70,000 | -53.0% | 12,004 | -46.0% | 0.00% | – |
| Q4 2020 | $149,000 | +69.3% | 22,250 | +85.4% | 0.00% | – |
| Q3 2020 | $88,000 | – | 12,004 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,340,207 | $3,089,073 | 5.63% |
| Stonepine Capital Management, LLC | 1,239,199 | $1,635,743 | 1.50% |
| Alta Fundamental Advisers LLC | 2,658,589 | $3,509,337 | 1.11% |
| BML Capital Management, LLC | 1,102,895 | $1,455,821 | 1.04% |
| Altium Capital Management LP | 1,012,368 | $1,336,326 | 0.54% |
| Bleichroeder LP | 1,326,085 | $1,750,432 | 0.52% |
| Nantahala Capital Management | 1,750,000 | $2,310,000 | 0.14% |
| Ikarian Capital, LLC | 466,019 | $619,806 | 0.11% |
| RTW INVESTMENTS, LP | 3,256,102 | $4,298,055 | 0.07% |
| Orbimed Advisors | 2,000,000 | $2,640,000 | 0.05% |